Article Data

  • Views 559
  • Dowloads 103

Original Research

Open Access

Expression of topoisomerase II, BCL-2, and Ki-67 in ovarian cancer tissue and their effects on the development and prognosis of ovarian cancers

  • E.N. Akyurek1
  • A.F. Yavuz Avsar2
  • U.M. Ural1
  • A. Kilicarslan3
  • M. Yildirim4,*,

1Recep Tayyip Erdogan University, School of Medicine, Department of Obstetrics and Gynecology, Rize, Turkey

2Yildirim Beyazit University, School of Medicine, Department of Obstetrics and Gynecology Ankara, Turkey

3Yildirim Beyazit University, School of Medicine, Department of Pathology, Ankara, Turkey

4Ankara Ataturk Training and Research Hospital, Obstetrics and Gynecology, Ankara, Turkey

DOI: 10.12892/ejgo3370.2017 Vol.38,Issue 5,October 2017 pp.675-679

Published: 10 October 2017

*Corresponding Author(s): M. Yildirim E-mail: melahatyildrim@yahoo.com

Abstract

Purpose: The objective of this study was to evaluate the role of the expression of topoisomerase II, BCL-2, and Ki-67 in an ovarian tissue and their effects on the development and the prognosis of ovarian cancers. Materials and Methods: The study consisted of 38 female patients with ovarian cancers. Patients' characteristics, tumor type, stage, and the grade of the disease, and topoisomerase II, Bcl-2, and Ki-67 values in ovarian tissue were compared. Results: Extensivenesses of topoisomerase II and Ki-67 staining in early-stage disease were found statistically different from those in the advanced stage diseases (for topoisomerase II, 60.38 ± 33.87% vs 85 ± 8.5%, p = 0.017, for Ki-67; 25.07 ± 25.04% vs 51±25.29%, p = 0.012). Differences of Bcl-2 staining between two groups were not significant (30.38 ± 38.82 % vs 18.2 ± 30.58%, p = 0.377). Conclusions: Expressions of topoisomerase II and Ki-67 in ovarian cancer tissues were associated with advanced stage diseases and expression of Bcl-2 refers to good histological grade in patients.

Keywords

Ovarian cancer; Topoisomerase II; Bcl-2; Ki-67; Cancer tissue.

Cite and Share

E.N. Akyurek,A.F. Yavuz Avsar,U.M. Ural,A. Kilicarslan, M. Yildirim. Expression of topoisomerase II, BCL-2, and Ki-67 in ovarian cancer tissue and their effects on the development and prognosis of ovarian cancers. European Journal of Gynaecological Oncology. 2017. 38(5);675-679.

References

[1] Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J.: “Cancer statistics”. CA Cancer J. Clin., 2008, 58, 71.

[2] Disaia P.J., Greasman W.T: “Epithelial ovarian cancer”. In: Disaia P.J., Greasman W.T. (eds). Clinical gynecology oncology. 5thed. St Louis: Mosby, 1997, 282.

[3] American Cancer Society: “Cancer facts and figures”. Atlanta, GA, 1999.

[4] Jacobs I., Bast R.C. Jr.: “The CA–125 tumor-associated antigen: a review of the literature”. Hum. Reprod., 1989, 4, 1.

[5] Bosari S., Moneghini L., Graziani D.: “Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas and adenocarsinomas”. Hum. Pathol., 1995, 26, 534.

[6] Emi M., Kim R., Tanabe K., Uchida Y., Toge T.: “Targeted therapy against Bcl-2- related proteins in breast cancer cells”. Breast Cancer Res., 2005, 7, 940.

[7] Lauwers G.Y., Scott G.V., Korpeh M.S.: “Immunohistochemical evaluation of bcl–2 protein expression in gastric adenocarsinomas”. Cancer, 1995, 75, 2209.

[8] Ozols R.F.: “Update on Gynecologic Ocology Group (GOG) trials in ovarian cancer”. Cancer Invest., 2004, 22, 11.

[9] Rodes J.: “Hormonal responses to large paracentesis: are discordant results due to technologic differences?” Hepatology, 1990, 11, 1087.

[10] Isola J., Kallioniemi O.P., Korte J.M., Wahlstrom T., Aine R., Helle M., et al.: “Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival”. J. Pathol., 1990, 162, 295.

[11] Kerns B.J., Jordan P.A., Faerman L.L., Berchuck A., Bast R.C. Jr., Layfield L.J.: “Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis”. Am. J. Clin. Pathol., 1994, 101, 192.

[12] Goff B., Ries J., Els L., Coltrera M., Gown A.: “Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure”. Gynecol. Oncol., 1998, 70, 378. 678.

[13] Wong W.S., Tattersall M.H.: “Immunohistochemical determination of tumor growth fraction in human ovarian carcinoma”. Br. J. Obstet. Gynaecol., 1989, 96, 720.

[14] Henriksen R., Strang P., Backstrom T., Wilander E., Tribukait B., Oberg K.: “Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers”. Anticancer Res., 1994, 14, 603.

[15] Layfield L.J., Saria E.A., Berchuck A., Dodge R.K., Thompson J.K., Conlon D.H., et al.: “Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis”. J. Surg. Oncol., 1997, 66, 230.

[16] Anttila M., Kosma V.M., Ji H., Wei-Ling X., Puolakka J., Juhola M., et al.: “Clinical significance of alpha-catenin, collagen IV, and Ki–67 expression in epithelial ovarian cancer”. J. Clin. Oncol., 1998, 16, 2591.

[17] Rustin G.J., Nelstrop A.E., McClean P., Brady M.F., McGuireW.P., HoskinsW.J., et al.: “Defining response of ovarian carsinoma to initial chemotherapy according to serum Ca125”. J. Clin. Oncol., 1996, 14, 1545.

[18] Ozols R.F.: “Treatment goals in ovarian cancer”. Int. J. Gynecol. Cancer, 2005, 15, 3.

[19] Noviello E., Aluigi M., Cimoli G., Rovini E., Mazzoni A., Parodi S., et al.: “Sister-chromatid exchanges, chromosomal aberrations and cytotoxicity produced by topoisomerase II-targeted drugs in sensitive (A2780) and resistant (A2780-DX3) human ovarian cancer cells: correlations with the formation of DNA double-strand breaks”. Mutat. Res., 1994, 311, 21.

[20] Huber A.O., Evan G.I.: “Cooperative interaction between c-myc and bcl– 2 rotooncogene”. Nature, 1992, 359, 554.

[21] Özkal S., Tuna B., Koyuncuoğlu M., Selma Ş., Emek Ö., Turhan U.: “Epitelyal over tümörleri ile Bcl-2, nm 23 ve c-erbB-2 ekspresyonları arasındaki ilişki”. Cerrahpaşa Tıp. Dergisi, 2002, 33, 79. [Article in Turkish]

[22] Gotlieb W., Goldberg I., Weisz B., Davidson B., Novikov I., Kopolovic J., et al.: “Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer”. Gynecol. Oncol., 2001, 82, 99.

[23] Brutsmann H.: “Expression of cellular apoptosis susceptibility protein serous ovarian carsinoma: a clinicopathologic and immunohistochemical study” Gynecol. Oncol., 2004, 92, 268.

[24] Chan W.Y., Cheung K.K., Schorge J.O., Huang L.W., Welch W.R., Bell D.A., et al.: “Bcl-2 and p53 protein expression, apoptosis and p53 mutation in human epithelial ovarian cancers”. Am. J. Pathol., 2000, 156, 409.

[25] Bélanger S., Côté M., Lane D., L'Espérance S., Rancourt C., Piché A.: “Bcl-2 decreases cell proliferation and promotes accumulation of cells in S phase without affecting the rate of apoptosis in human ovarian carcinoma cells”. Gynecol. Oncol., 2005, 97, 796.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top